# Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

> **NCT04439305** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Advanced Lymphoma
- Advanced Malignant Solid Neoplasm
- Hematopoietic and Lymphoid Cell Neoplasm
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT04439305
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-02-25
- **Primary completion:** 2018-06-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** zero accrual
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439305, "Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04439305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*